Generic Drug Manufacturer Hikma Providing Credits for 340B Overcharges

Hikma Pharmaceuticals USA, the U.S. division of U.K.-based generic drug manufacturer Hikma Pharmaceuticals plc, is crediting 340B covered entities for overcharges on a long list of NDCs from the fourth quarter of 2017 through the fourth quarter of 2020.

The company announced the credits in a notice posted last week on the U.S. Health Resources and Services Administration website. Apexus, the 340B prime vendor, is working with wholesalers to process the credits on Hikma’s behalf.

Editor at Large | Website | + posts